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-linked adrenoleukodystrophy (X-ALD) is a demy-
elinating disease due to mutations in the 
 
ABCD1
 
(
 
ALD
 
) gene, encoding a peroxisomal ATP-binding
cassette transporter (ALDP). Overexpression of adreno-
leukodystrophy-related protein, an ALDP homologue
encoded by the 
 
AB
 
CD2 (
 
adrenoleukodystrophy-related
 
)
gene, can compensate for ALDP deﬁciency. 4-Phenyl-
butyrate (PBA) has been shown to induce both 
 
ABCD2
 
expression and peroxisome proliferation in human ﬁbro-
blasts. We show that peroxisome proliferation with unusual
shapes and clusters occurred in liver of PBA-treated
X
 
rodents in a PPAR
 
 
 
-independent way. PBA activated
 
Abcd2
 
 in cultured glial cells, making PBA a candidate
drug for therapy of X-ALD. The 
 
Abcd2
 
 induction observed
was partially PPAR
 
 
 
 independent in hepatocytes
and totally independent in ﬁbroblasts. We demonstrate
that a GC box and a CCAAT box of the 
 
Abcd2
 
 promoter
are the key elements of the PBA-dependent 
 
Abcd2
 
 induc-
tion, histone deacetylase (HDAC)1 being recruited by
the GC box. Thus, PBA is a nonclassical peroxisome
proliferator inducing pleiotropic effects, including effects
at the peroxisomal level mainly through HDAC inhibition.
 
Introduction
 
X-linked adrenoleukodystrophy (X-ALD; OMIM 300100) is an
inherited disorder characterized by progressive demyelination
of the central nervous system and adrenal insufficiency (Moser
et al., 2001). X-ALD is associated with an accumulation of
very long-chain fatty acids (VLCFA) in plasma and tissues.
The disease is due to mutations in the 
 
ABCD1
 
 (ALD) gene
located in Xq28 (Mosser et al., 1993). 
 
ABCD1
 
 encodes the pro-
tein ALDP, a peroxisomal member of the ATP-binding cassette
family, which is thought to participate in the entry of VLCFA
into the peroxisome where VLCFA are 
 
 
 
-oxidized. ALDP is a
half-transporter, which is supposed to function as a homodimer
or a heterodimer, in association with one of the three other
peroxisomal ATP-binding cassette half-transporters, ALDRP
(adrenoleukodystrophy-related protein), which is the closest
homologue of ALDP (Lombard-Platet et al., 1996), PMP70
(70-kD peroxisomal membrane protein; Kamijo et al., 1990),
and PMP69 (Holzinger et al., 1997). These transporters
are encoded by the 
 
ABCD2
 
 (
 
Adrenoleukodystrophy-related
 
),
 
ABCD3
 
, and 
 
ABCD4
 
 genes, respectively, and their function is
still unclear. Overexpression of ALDRP has been demonstrated
to compensate for ALDP deficiency in 
 
Abcd1
 
 
 
 
 
/
 
 
 
 mice, thus
preventing VLCFA accumulation and the onset of a neurological
phenotype (Pujol et al., 2004). Furthermore, restoration of
VLCFA 
 
 
 
-oxidation could be obtained in X-ALD human fibro-
blasts transfected with 
 
Abcd2
 
 cDNA (Braiterman et al., 1998;
Kemp et al., 1998; Flavigny et al., 1999; Netik et al., 1999;
Fourcade et al., 2001). Therefore, pharmacological induction
of this partially redundant gene could be a therapeutic strategy
for X-ALD. We have shown that fibrates up-regulate 
 
Abcd2
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expression (Albet et al., 1997, 2001; Berger et al., 1999; Four-
cade et al., 2001) in the liver of rodents. Fibrates can restore
 
 
 
-oxidation of VLCFA in the liver of 
 
Abcd1
 
 
 
 
 
/
 
 
 
 mice (Netik et
al., 1999) but not in brain, possibly due to obstacle of the blood–
brain barrier (Waddell et al., 1989; Berger et al., 1999). Fibrates,
commonly used as hypolipidemic drugs in human medicine, are
peroxisome proliferators (PPs) in rodents. PPs are ligands of a
member of the steroid nuclear receptor family named PPAR
 
 
 
(PP-activated receptor 
 
 
 
). PPAR
 
 
 
 up-regulates expression of
target genes involved in lipid metabolism by binding to a DNA
sequence called PPRE (PP response element). However, such a
functional PPRE has not been found in the 
 
Abcd2
 
 promoter
(Gartner et al., 1998; Fourcade et al., 2001).
4-Phenylbutyrate (PBA) treatment can restore 
 
 
 
-oxida-
tion of VLCFA and increase 
 
ABCD2
 
 expression in fibroblasts
from X-ALD patients and 
 
Abcd1
 
 
 
 
 
/
 
 
 
 mice (Kemp et al.,
1998). Furthermore, dietary PBA was shown to be efficient in
vivo to reduce the VLCFA levels in the brain of 
 
Abcd1
 
 
 
 
 
/
 
 
 
mice, but 
 
Abcd2
 
 expression has not been analyzed (Kemp et al.,
1998). Interestingly, the authors observed a 2.4-fold increase in
the number of peroxisomes in 5 mM PBA-treated control or
X-ALD human fibroblasts, which was not accompanied by induc-
tion of the 
 
PPAR
 
 
 
 and peroxisomal 
 
Acyl-CoA Oxidase
 
 (
 
AOX
 
)
genes but could be linked to the observed induction of the
 
PEX11
 
 
 
 gene. This hypothesis was strengthened by the dem-
onstration that PBA-mediated hepatic peroxisome proliferation
is absent in 
 
Pex11
 
 
 
 
 
 
 
/
 
 
 
 mice (Li et al., 2002). Classical PPs
do not cause peroxisome proliferation in humans, and fibro-
blasts are not known to be the target cells for PPs. Moreover,
both peroxisome proliferation and 
 
PPAR
 
 
 
 and 
 
Aox
 
 induction
occur in PP-treated rodents. Kemp et al. (1998) reported induc-
tion of 
 
PPAR
 
 
 
, but not of 
 
Aox
 
, in PBA-treated mice fibroblasts.
By contrast, activation of a reporter plasmid containing the rat
 
Aox
 
 PPRE has been obtained in PBA-treated mouse hepatoma
cells (Pineau et al., 1996) and the binding of PBA to PPAR
 
 
 
has been demonstrated using C6 rat glioma cells (Liu et al.,
2002). It should also be noticed that an increased expression of
PPAR
 
 
 
 has been observed in PBA-treated human glioma cells
(Pineau et al., 1996). Together, the data indicate that PBA, a
compound structurally related to fibrates, is a PP that acts par-
tially through noncanonical mechanisms.
Sodium butyrate induces a variety of alterations at the
molecular and cellular levels. Transcriptional activation, as a
result of the inhibition of histone deacetylase (HDAC) activity
could represent the main mechanism of action of butyrate
(Davie, 2003). PBA, a butyrate analogue, displays also similar
pleiotropic effects in vitro and in vivo. It has been reported that
PBA induces hyperacetylation of histones (Lea and Randolph,
1998; Warrell et al., 1998). Deacetylase inhibition may account
for 
 
ABCD2
 
 induction observed in PBA-treated fibroblasts and
probably for 
 
PEX11
 
 
 
 induction, which might be responsible
for the PPAR
 
 
 
-independent peroxisome proliferation.
Our main objective was to compare the effects of PBA,
butyrate, and fibrate on the expression of 
 
Abcd2
 
 and 
 
Aox
 
 and
peroxisome proliferation in vivo in the liver and brain of rats
and in vitro in hepatic and glial cells. The molecular mechanism
of the PBA regulation of 
 
Abcd2
 
 expression was also studied.
 
Results
 
PBA up-regulates expression of the 
 
Abcd2
 
 and 
 
Aox
 
 genes in liver but not in 
brain
 
Because the liver is the main target tissue for PPs and demyelin-
ation occurs in the brain of X-ALD patients, we evaluated the
impact of PBA on peroxisomal gene expression in these tissues.
Rats were treated per os with PBA as described by Kemp et al.
(1998) (dose 
 
 
 
1) and also with a higher dose (dose 
 
 
 
1.5) during
6–9 wk. Expression of the 
 
Abcd2
 
 and 
 
Aox
 
 genes was increased in
the liver (Fig. 1 A), with marked interindividual variations as it
was already seen for PPAR
 
 
 
 (Lemberger et al., 1996). No signif-
icant difference could thus be obtained between the two doses
(Fig. 1 B). Considering the 10 treated animals, the average induc-
tion was 1.9- and 1.5-fold for the 
 
Abcd2
 
 and 
 
Aox
 
 genes, respec-
tively. Gene induction was observed neither in the brain (Fig. 1
A) nor in the spleen, kidney, and testis (unpublished data).
Figure 1. Expression of the Abcd2 and Aox genes is up-regulated by PBA
in liver. (A) RNA samples from liver and brain of a control rat and from a rat
treated per os with PBA (dose  1.5) for 9 wk were analyzed by RT-PCR in
duplicates. (B) RNA was extracted from liver of control rats (n   10) and rats
treated with PBA (dose  1) for 6–7 wk (n   6) or PBA (dose  1.5) for 6–9
wk (n   4). Samples were individually analyzed twice by RT-PCR. The inten-
sities for Abcd2 and Aox mRNA were quantified by digital imaging and
normalized using glyceraldehyde-phosphate dehydrogenase (Gapdh) inten-
sities. Data (means   SD) are presented as fold induction in relation to the
values for control rats (taken equal to 1 and not depicted in the figure). (C) 2
mg sodium ciprofibrate (Cipro) or 20 mg PBA in 100  l of water was
injected into the cerebral fourth ventricle (100  l/h). Control rats received
equiosmolar amounts of NaCl. RNA was extracted from the whole brain and
analyzed individually by Northern blotting (n   4 for each group of rats).REGULATION OF ABCD2 BY PHENYLBUTYRATE • GONDCAILLE ET AL. 95
Induction of peroxisomal genes by PPs usually starts sev-
eral hours after the beginning of a treatment (Motojima, 1997).
Because a unique IP injection of PBA (400 mg/kg) was suffi-
cient to weakly induce (1.5-fold) the expression of a PP-sensi-
tive gene (CYP4A1; Pineau et al., 1996), we injected 720 mg of
PBAper kilogram per day i.p. for 3 d and analyzed mRNA
from liver, brain, intestine, muscle, spleen, kidney, and lung.
No induction of the Abcd2 and Aox genes was obtained in the
seven examined tissues (unpublished data).
The absence of gene induction in the brain after long- and
short-term treatments, which could result from a rapid catabo-
lism (the half-life of PBA is  1–2 h), prompted us to perfuse
PBA directly in the fourth ventricle. No induction of the two
peroxisomal genes was found in the brain examined as a whole
(Fig. 1 C). In the same way, no change in the gene expression
was obtained when ciprofibrate was perfused under the same
experimental conditions.
PBA treatment induces peroxisome 
proliferation in liver along with 
appearance of peroxisomal phi-bodies 
and clusters
Peroxisomes were observed in the liver of each control and of
each per os PBA-treated rat by light microscopy (LM) and EM.
When comparing the pooled data from all the treated rats (n  
10) with the pooled data from all the control rats (n   10), per-
oxisome proliferation was clearly demonstrated. LM examina-
tion showed that the number of peroxisomes per cellular area
was higher in the treated animals than in the control animals
( 1.4; P   0.05). By EM morphometric analysis, significantly
higher numerical density ( 2.3; P   0.001), volume density
( 2.3; P   0.01), and surface density ( 2.2; P   0.01) versus
controls were found in the treated rats, giving evidence of perox-
isome proliferation (Fig. 2, A and B). Although the average size
of peroxisomes was not significantly different in the control and
treated rats, a small percentage of peroxisomes in 8 out of 10
treated animals had very large size (D-circle 2.7-fold that of
control peroxisomes) and showed peculiar shapes (phi-bodies;
Fig. 2 D). These phi-bodies were present in multiple fragments
of the same liver and mostly located in the periportal areas. Phi-
bodies were never seen in control livers. Furthermore, clusters
of up to 10 peroxisomes were present in the rats treated with
dose  1.5 (Fig. 2 B), whereas in the control rats as well as in the
rats treated with dose  1, only clusters of two to three peroxi-
somes were seen (peroxisomes are considered to belong to a
cluster when the distance between neighboring organelles is
smaller than twofold of the mean diameter of the peroxisomes of
the cluster). The clusters often showed nearly touching peroxi-
somes (Fig. 2 C). Finally, heterogeneity in the reaction product
of catalase activity was detected in proliferated peroxisomes,
which was not observed in control rats. AOX was located in per-
oxisomes by EM immunodetection (Fig. 2 E). The mean label-
Figure 2. PBA induces peroxisome proliferation in
liver. (A–D) Peroxisomes were stained for catalase
activity. Liver of a control rat (A) and a rat treated per
os with PBA (dose  1.5) for 6 wk (B). Note peroxi-
some clusters and a phi-shaped peroxisome (arrow-
head) in B. (C) Nearly touching peroxisomes suggesting
a fission or budding process (Roels, 1991) in liver of
a rat treated with PBA (dose  1) for 6 wk. (D) Four
phi-shaped peroxisomes in liver of a rat treated as in
C. Unstained nucleoids are clearly visible in several
peroxisomes. (E) Immunogold localization of AOX in
a phi-shaped peroxisome, adjacent to an unlabeled
mitochondrion, in liver of a rat treated as in C.
Bars: (A, B, D, and E) 1  m; (C) 100 nm.JCB • VOLUME 169 • NUMBER 1 • 2005 96
ing density for AOX was increased by a factor of 1.3 in PBA-
treated rats (n   3) in comparison with control rats (n   3). In
addition, when the volume density of the peroxisomes was taken
into account, the total labeling differed by a factor 2.5 between
the control and treated rats. Although not significant, these dif-
ferences are in agreement with RT-PCR data (Fig. 1, A and B).
A weak but significant dose effect was observed in the
liver of the PBA-fed rats. The number of peroxisomes per cellu-
lar area measured by LM increased by 1.4-fold with dose  1
and 1.7-fold with dose  1.5. Furthermore, the EM morphome-
try values were always higher in the liver of rats (n   4) treated
with dose  1.5 (numerical density:  2.7, volume density:
 3.1, and surface density:  2.9) than in the rats (n   6) treated
with dose  1 ( 2.1,  1.9, and  1.8, respectively). A peroxi-
some proliferation index was calculated for each treated animal
(n   10) versus the mean value of 10 control animals consider-
ing successively the number of peroxisomes per cellular area
measured by LM and each of the three EM morphometry val-
ues. When the four proliferation factors of each treated animal
were ranked (n   40), the dose effect was significant (P  
0.001). In fact, the different animals did not respond to the PBA
treatment to the same extent with regard to the number of perox-
isomes, as it was observed already for the induction of peroxi-
somal genes (Fig. 1 B). In some animals, a clear proliferative ef-
fect co-occurred with a higher induction of peroxisomal genes.
The number of peroxisomes per cellular area was studied
by LM in the kidney (tubulus contortus I cells) and the intesti-
nal epithelium, two PP-sensitive tissues, and showed no signif-
icant differences between the control rats (n   3) and the per os
treated rats (n   3) with dose  1 of PBA.
In the rats i.p. injected with PBA during 3 d, LM exami-
nation revealed no peroxisome proliferation in the liver, in
agreement with the absence of induction of peroxisomal genes
as mentioned in the previous paragraph.
PBA treatment modifies the peroxisome 
distribution in ependymal cells of the 
fourth ventricle
Peroxisomes were also studied by EM in ependymal cells lin-
ing the fourth ventricle of control rats (n   7) and per os PBA-
treated rats with doses  1 (n   3) or  1.5 (n   3). A 1.4-fold
(P   0.05) increase in the number of peroxisomes per cytoplas-
Figure 3. PBA modifies peroxisome distribution in ependymal cells of the
fourth ventricle. Peroxisomes were stained for catalase activity. Peroxi-
somes in cells of a control rat (A) or a rat treated per os with dose  1 of
PBA for 6 wk (B). Peroxisomes are small and few when compared with
liver (Fig. 2). Peroxisome clusters as shown in B were more frequently
observed in treated animals. Cilium is seen in A. Bars, 200 nm.
Figure 4. Peroxisomal genes are inducible by PBA and butyrate in hepa-
tocytes. Rat primary hepatocytes were cultured in the presence of different
concentrations of PBA, butyrate, and ciprofibrate for 72 h. Total RNA was
analyzed by RT-PCR for Abcd2 and Aox expression. Results are presented
as fold induction in relation to the control values for cells cultured in the
absence of drug. Control data, taken equal to 1, are not reported in
the figure. Data represent means   SD of two independent experiments.REGULATION OF ABCD2 BY PHENYLBUTYRATE • GONDCAILLE ET AL. 97
mic area occurred together with more frequent clusters ( 2.0;
P   0.05) (Fig. 3). However, EM revealed no difference in
ependymal cells of the choroid plexus or lining the lateral wall
of the lateral ventricle and in stem cells of the subventricular
zone. These stem cells contained only very few and small cata-
lase particles.
When PBA was infused directly into the fourth ventricle,
no effect on peroxisomes was observed by EM in ependymal
cells, whereas infusion of ciprofibrate caused a decrease ( 0.67;
P   0.05) in the number of peroxisomes per cell profile.
PBA and butyrate induce expression 
of peroxisomal genes and proliferation 
of peroxisomes in primary cultures of 
hepatocytes
Considering the short half-life of butyrate in living animals
( 6 min), primary cultures of rat hepatocytes were treated with
butyrate, PBA, and ciprofibrate for 72 h to gain insight into the
mechanisms involved in the regulation of gene expression and
peroxisome biogenesis. PBA and butyrate displayed a similar
dose-dependent activation of Abcd2 expression (Fig. 4). How-
ever, the increase in Aox mRNA levels was lower after butyrate
treatment than after PBA treatment (Fig. 4). Furthermore, the
Abcd2 expression level relative to Aox level was higher with
PBA and butyrate than with ciprofibrate (Fig. 4). Therefore, the
effects on peroxisomal gene expression in primary hepatocytes
appeared to be different for the three compounds.
Catalase-stained peroxisomes were visualized in hepato-
cytes by LM. The number of peroxisomes per cellular area was
increased 1.4-fold (P   0.01) in PBA-treated cells versus con-
trols for dose 1.25 mM and 1.8-fold (P   0.001) for dose 2.5
mM. An increase was also seen when cells were treated with
butyrate: 1.3-fold (P   0.05) for dose 1.25 mM and 1.4-fold (P  
0.01) for dose 2.5 mM. A similar increase ( 1.7; P   0.001)
was obtained after 0.25 mM ciprofibrate treatment.
PBA and butyrate, but not ciprofibrate, 
induce Abcd2 expression and peroxisome 
proliferation in cultured glial cells
In the prospect of a possible pharmacological therapy of X-ALD,
it is relevant to try to induce Abcd2 expression in glial cells. In
differentiated CG4 cells, pure primary astrocytes, and mixed
primary cultures of glial cells, we observed a dose-dependent
induction of Abcd2 expression after PBA or butyrate treatment
but no effect on Aox expression (Fig. 5, A and B). When the
glial cells were treated with 0.25 and 0.5 mM ciprofibrate, we
observed no change in the Abcd2 and Aox expression in the
three types of cell culture (unpublished data).
We also examined the peroxisomes by LM after immu-
nolocalization of catalase in C6 rat glioma cells treated with 5
mM PBA or 0.5 mM ciprofibrate. The number of peroxisomes
per cellular area was significantly higher in PBA-treated cells
than in controls ( 2.0; P   0.01) but remained unchanged in
ciprofibrate-treated cells. The PBA treatment generated a change
in cell morphology, characterized by a fibroblastic aspect, which
was much less marked when cultures were treated with ciprofi-
brate (unpublished data).
PBA induction of the Abcd2 gene and 
peroxisome proliferation does not 
require PPAR 
We have previously shown that fenofibrate induction of Abcd2
and Aox in the liver of rodents requires the presence of PPAR 
(Fourcade et al., 2001). To test whether or not PBA induction
of the peroxisomal genes is dependent on PPAR , fibroblasts
from control and PPAR   /  mice were treated with PBA or
fenofibrate and mRNA was analyzed. In contrast to hepato-
cytes (Fig. 4), the peroxisomal genes in control fibroblasts
were not induced by fenofibrate (Fig. 6 A), as observed in glial
cells (unpublished data). PBA elicited the same dose-depen-
dent induction of Abcd2 in both PPAR   /  and PPAR   / 
Figure 5. Abcd2 is inducible by PBA and butyrate in
glial cells. Differentiated CG-4 oligodendrocytes, pure
primary astrocytes, and mixed primary cultures of
oligodendrocytes and astrocytes were treated with
different concentrations of PBA (A) and butyrate (B)
for 72 h. Gene expression was analyzed by RT-PCR.
Results are means   SD of three independent experi-
ments and presented as in Fig. 4.JCB • VOLUME 169 • NUMBER 1 • 2005 98
fibroblasts, indicating that it does not require PPAR  to acti-
vate Abcd2 (Fig. 6 A). The changes in expression of Aox in the
PBA-treated fibroblasts were too weak (as already observed in
PBA-treated normal fibroblasts by Kemp et al. [1998]) to con-
clude whether or not their induction by PBA is PPAR  depen-
dent (Fig. 6 A). Similar results were obtained using hepato-
cytes, except that PBA induction of Abcd2 was significantly
higher in PPAR   /  cells than in PPAR   /  cells (Fig. 6
B), indicating that the extra induction of Abcd2 in normal hepa-
tocytes is PPAR  dependent. Furthermore, the peroxisome
proliferation induced by PBA in control hepatocytes (see the
section PBA and butyrate induce expression of peroxisomal
genes and proliferation of peroxisomes in primary cultures of
hepatocytes) was maintained in PPAR   /  hepatocytes (Fig.
6, C and D) as the peroxisome number measured by LM was
increased in cells treated with 2.5 ( 1.7; P   0.05) and 5.0
mM PBA ( 1.4; P   0.05). This result was confirmed using
EM ( 2.7 in 5.0 mM PBA-treated cells).
Trichostatin A (TSA), a potent HDAC 
inhibitor, increases Abcd2 expression in 
hepatocytes only at high doses
From these results, we hypothesized that in hepatocytes only
part of PBA induction of Abcd2 can be ascribed to HDAC in-
hibition, and the other part to PPAR  activation. To test this
hypothesis, we treated rat primary hepatocytes with TSA, a
specific inhibitor of HDAC at nanomolar concentrations, us-
ing different doses (0.03–3  M) and times (24, 48, and
72 h). Expression of Abcd2 was enhanced only at high doses
(1–3  M) of TSA, and the response was limited ( 1.6 on
average; Fig. 7).
Dose-dependent induction of the Abcd2 
promoter by PBA or butyrate requires 
only the basic promoter
The rat Abcd2 promoter contains a CCAAT box ( 53) sur-
rounded by two putative GC boxes respectively located at  65
(GC2: CCGCCC) and  35 (GC1: GGGTGG), the three motifs
being very well conserved in mouse and human (Fourcade et
al., 2001). To identify the molecular mechanism of induction
by PBA, COS-7 cells were transiently transfected with a plas-
mid construct (p277) containing the first 83 bp of the promoter
(Fourcade et al., 2001) upstream from the luciferase reporter
gene. Transfected cells were then exposed to different doses of
PBA or butyrate for 36 h and analyzed for their luciferase ac-
tivity. Under fibrate treatment, the construct was unable to me-
diate any induction in similar experiments (Fourcade et al.,
2001). In the presence of PBA or butyrate, we observed a
strong dose-dependent induction (Fig. 8 A). Similar results
were obtained with the p2206 construct containing 2 kb of the
Figure 6. PBA causes Abcd2 induction and
peroxisome proliferation in PPAR   /  cells.
Fibroblasts (A) and hepatocytes (B) were
prepared from fetal and adult liver, respectively,
of PPAR   /  and PPAR   /  mice and
exposed to PBA or fenofibrate (Feno) for 72 h.
Gene expression was analyzed by RT-PCR.
Data are means   SD of two to five indepen-
dent experiments and presented as in Fig. 4.
Untreated (C) or 2.5 mM PBA-treated (D)
hepatocytes from PPAR   /  mice were ex-
amined for the number of peroxisomes by LM
after anti-catalase protein A–gold immuno-
labeling with silver enhancement. Bars, 20  m.
Figure 7. TSA, a potent HDAC inhibitor, induces Abcd2 expression.
Rat primary hepatocytes were treated with different doses of TSA and for
different times. Abcd2 expression was analyzed by RT-PCR. Results from
three independent experiments are presented as fold induction of the
control values (equal to 1) for untreated cells.REGULATION OF ABCD2 BY PHENYLBUTYRATE • GONDCAILLE ET AL. 99
promoter (p2206) (unpublished data), indicating that the basic
promoter (83 bp) is sufficient to mediate full induction of the
Abcd2 gene by PBA.
PBA-response and basal activity of the 
Abcd2 promoter depends on a GC box 
and a CCAAT box
It has been reported that mutation or deletion of a GC box can
abolish the response to butyrate (Lu and Lotan, 1999) and
that  HDAC1 can repress transcription by direct interaction
with Sp1 and Sp3 (Doetzlhofer et al., 1999; Davie, 2003).
The CCAAT box has also been demonstrated to play an impor-
tant role in gene activation by HDAC inhibitors through the
CCAAT-binding protein NF-Y (a trimeric association of NF-
YA, NF-YB, and NF-YC) and recruitment of histone acetyl
transferase (HAT) activity (McCaffrey et al., 1997; Jin and
Scotto, 1998). Therefore, we further analyzed the role of the
GC and CCAAT boxes in the basal activity of the Abcd2 pro-
moter and in the context of PBA induction.
We first compared in independent experiments the ac-
tivity of p277 with the activities of p277 1, p277 2, and
p277 1,2 (where one or both GC boxes is mutated; Fig. 8 B) or
with the activities of p243 (construct devoid of 34 bp of the 5 
region containing the GC2 and CCATT boxes), p277 5UTR,
and p243 5UTR (constructs devoid of 52 bp of the 5  untrans-
lated region) (Fig. 8 C). Mutation of the GC1 box markedly de-
creased the basal activity of the reporter gene (3.6- and 5.6-fold
reduction for p277 1 and p277 1,2, respectively), underlining
the functional importance of this GC box for basal Abcd2 ex-
pression (Fig. 8 B). By contrast, mutation of the GC2 box
caused a minor decrease in basal activity (Fig. 8 B). Deletion of
the 34 bp containing the GC2 and CCATT boxes displayed a
3.2-fold decrease in the basal activity, which is more pro-
nounced than the one observed with p277 2 (1.3-fold; Fig. 8
C). This observation suggests a functional role for the CCAAT
box in the basal activity of the promoter. Moreover, basal
activity of p277 5UTR was 1.5-fold higher, suggesting that
some repression was mediated through the deleted 5 -UTR se-
quence. However, deletion of the 5 -UTR sequence in the p243
construct did not show any difference (Fig. 8 C).
Interestingly, the effect of PBA and butyrate treatment
was abolished by the mutation of the GC1 box, indicating that
the GC1 box is not only essential for basal activity but is also
the key element of the activation by PBA or butyrate (Fig. 8 B).
This capability of induction was also decreased in the p243 con-
struct (1.8-fold induction) showing that the presence of the GC1
box is sufficient to mediate PBA induction but suggesting that
the presence of the CCAAT box (which is not sufficient alone;
see p277 1,2) is necessary to mediate full induction by PBA
(Fig. 8 C). Deletion of the 5 -UTR sequences did not alter sig-
nificantly the levels of induction by PBA or butyrate (Fig. 8 C).
The GC1 and CCAAT boxes bind their 
cognate factors, and HDAC-1 is 
recruited through the GC1 box
To explore the capability of the GC1 and CCAAT boxes of the
Abcd2 promoter to bind in vitro Sp1 or Sp3 and NF-Y, respec-
tively, we first performed electrophoretic mobility shift assay
(EMSA) with the corresponding radiolabeled oligonucleotides.
Several DNA–protein complexes were formed in the presence
of nuclear extracts from rat liver (Fig. 9 A, lanes 2 and 10).
These complexes were sequence-specific because they disap-
peared in the presence of an excess of unlabeled homologous
oligonucleotide (Fig. 9 A, lanes 3 and 11) but not in the pres-
ence of an excess of unlabeled mutated oligonucleotide (Fig. 9
A, lanes 4 and 12). To investigate if the retarded complexes re-
sult from the binding of Sp1/Sp3 and NF-Y, we performed
EMSA in the presence of the specific antibodies. Incubation
with the anti-Sp1 and/or anti-Sp3 antibodies resulted in spe-
cific supershifted complexes for both antibodies, indicating
that the GC1 box binds Sp1 and Sp3 (Fig. 9 A, lanes 5–7). A
supershift was also obtained with the anti–NF-YA antibody
Figure 8. The GC and CCAAT boxes control basal expression and allow
full induction of the basic Abcd2 promoter by PBA and butyrate. COS-7
cells were cotransfected with constructs containing normal or mutated
Abcd2 promoter upstream of the luciferase reporter gene and pCMV- Gal
to allow normalization of the luciferase activity. Mutations of the GC and
CCAAT boxes and deletions are indicated in the schematic diagram.
The cells were cultured with or without different doses of PBA or butyrate.
(A) Analysis of the dose-dependent effect of PBA and butyrate. (B) Analysis
of the role of the GC boxes. (C) Analysis of the role of the CCAAT box
and of 5 UTR sequence. In each experiment, results are presented in rela-
tion to the luciferase activity of untreated p277-transfected cells taken
equal to 1. Fold induction showing the effect of the treatment for each
construct is indicated. Data are shown as means   SD of three to six
independent experiments performed in triplicate wells.JCB • VOLUME 169 • NUMBER 1 • 2005 100
and the CCAAT probe (Fig. 9 A, lane 13), demonstrating that
the CCAAT box binds NF-Y.
We further investigated by DNA affinity precipitation as-
say (DAPA) if the GC1 motif could be involved in the recruit-
ment of HDAC1. We used the biotinylated oligonucleotides
corresponding to the GC1 and mutated GC1 sequences used in
EMSA. The presence of HDAC-1 was detected in the precipi-
tated complexes obtained with the normal GC1 box but not
with the mutated motif (Fig. 9 B). This finding indicates that
HDAC-1 is recruited through interaction with the Sp1/Sp3 fac-
tors bound to the GC1 box of the Abcd2 promoter.
Discussion
Because PBA induces peroxisome proliferation in human fi-
broblasts, PBA has been described as a new PP (Kemp et al.,
1998). However, the fact that AOX and PPAR  expression was
unchanged in these cells indicates that PBA may induce perox-
isome proliferation through a mechanism not shared by classi-
cal PPs such as fibrates. To clarify this point, we studied the ef-
fects of PBA in rodent tissues and cells. Induction of the Abcd2
and Aox expression and of the peroxisome proliferation in the
liver of rats was moderate and occurred only after a long-term
(6–9-wk) treatment with high doses of PBA. The observed al-
terations in the shape (phi-bodies) and in the distribution (clus-
ters and nearly touching organelles) of peroxisomes are remi-
niscent of PP-induced modifications already described in rat
liver (Svoboda and Azarnoff, 1966; Baumgart et al., 1989;
Gorgas and Krisans, 1989; Roels, 1991) and rat hepatoma cells
(Duclos et al., 1997). It has been shown that overexpression of
Pex11p in rodent or human cells causes peroxisome prolifera-
tion, characterized by initial conversion of peroxisomes from
spherical vesicles into elongated tubules followed by appear-
ance of numerous small vesicular peroxisomes (Passreiter et
al., 1998; Schrader et al., 1998; Li and Gould, 2002). In the
liver of rodents treated with PPs, peroxisome proliferation and
peroxisomal gene induction occur early. In contrast, PBA had
no effect when a short-term treatment (3 d) was given to rats,
suggesting a different mode of action. However, the absence of
effect could result from the rapid metabolism of PBA to phen-
ylacetate leading to ineffective PBA plasma levels. Therefore,
we exposed primary hepatocytes to high concentrations of
PBA for 3 d and observed induction of the peroxisomal genes
and peroxisome proliferation hardly higher than in vivo, indi-
cating that PBA is a low-potent PP. It is well known that the
peroxisome proliferation in the rodent liver due to classical PPs
is totally suppressed in PPAR   /  mice (Lee et al., 1995). In
contrast, the present work shows that the PBA-induced peroxi-
some proliferation is maintained in PPAR   /  hepatocytes.
Both PBA and classical PPs induce Pex11  expression in
mammals (Abe and Fujiki, 1998; Abe et al., 1998; Kemp et al.,
1998; Schrader et al., 1998; Depreter et al., 2002). Surpris-
ingly, Pex11  is dispensable for peroxisome proliferation me-
diated by PPAR  activators, whereas Pex11  is required for
peroxisome proliferation in response to PBA (Li et al., 2002).
Furthermore, PBA but not fibrates induces peroxisome prolif-
eration in nonhepatic cells (where PPAR  expression is lower
than in hepatocytes), namely fibroblasts (Kemp et al., 1998)
and C6 cells (the present study). In summary, the requirement
of PPAR  and Pex11  for peroxisome proliferation and the
cell type where peroxisome proliferation can occur are differ-
ent for PBA and classical PPs. This finding indicates that the
mechanism of peroxisome proliferation in response to PBA is
distinct from that used by PPs.
X-ALD is characterized by demyelination in the brain. In
the context of a pharmacological therapy based on the partial
functional redundancy of the peroxisomal transporter ALDRP
there is considerable interest to explore the effects of PBA in the
brain. PBA is likely to cross the blood–brain barrier because it is
effective in lowering VLCFA levels in the brain of Abcd1  / 
mice (Kemp et al., 1998). Indeed, modifications at the peroxi-
somal level were detected in ependymal cells of the fourth ven-
tricle in PBA-treated rats. Unfortunately, no induction in peroxi-
somal gene expression was seen in the brain examined as a
whole. Nevertheless, the induction of Abcd2 that we observed in
PBA-treated glial cells might account for the restoration of VL-
CFA peroxisomal  -oxidation in the brain of PBA-treated
Abcd1  /  mice described by Kemp et al. (1998).
The knowledge of the molecular mechanism underlying
the PBA effects on Abcd2 expression may provide leads in
searching for new drugs for X-ALD therapy. We compared
PBA with ciprofibrate or fenofibrate (classical powerful PPs)
and with butyrate (an HDAC inhibitor) for their effects on per-
oxisomal gene expression in hepatic or nonhepatic cell cul-
Figure 9. Sp1/Sp3 and NF-Y bind to the GC1 and CCAAT boxes and
HDAC1 is recruited through the GC1 box. (A) EMSA was performed using
the 
32P-labeled GC1 or CCAAT oligonucleotides with 10  g of nuclear
extracts (NE) from rat liver. Competition experiments were performed with
a 50-fold molar excess of unlabeled oligonucleotides. Supershifts were
performed using specific antibodies or serum for control. Retarded com-
plexes are indicated. (B) DAPA was performed with the same nuclear
extracts using the biotinylated normal or mutated GC1 oligonucleotide.
Complexed proteins were resolved by SDS-PAGE and revealed by Western
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tures. First, in fibroblasts and glial cells, fibrate was unable to
induce Abcd2, suggesting that a cofactor of PPAR  is missing
or that the PPAR  level is too low (Lemberger et al., 1996). In
contrast,  Abcd2 was activated by PBA or butyrate in these
cells, and we demonstrated that the activation is PPAR  inde-
pendent. Furthermore, in hepatocytes, Abcd2 and Aox were in-
duced by PBA, butyrate, and ciprofibrate, with some differ-
ences for the three compounds. We had observed that the
induction of these genes by fibrate was completely abolished in
the liver of PPAR   /  mice (Fourcade et al., 2001). Here, we
show that PBA induction of Abcd2 is only reduced in PPAR 
 /  hepatocytes, suggesting that part of the induction is
PPAR  dependent and that the other part would originate in
the same mechanism underlying the activation of Abcd2 by
PBA and butyrate in nonhepatic cells. Similar conclusions can
be drawn from our experiments on TSA-treated hepatocytes.
Altogether, the results indicate that PBA and butyrate would
mainly activate Abcd2 by HDAC inhibition, whereas in hepato-
cytes an extra induction occurs through PPAR . This PPAR -
dependent induction is in agreement with the relatively high
level of PPAR  in hepatocytes and the capacity of PBA to bind
PPAR  (Liu et al., 2002).
HDAC is known to interact with the transcription com-
plex and the chromatin in a DNA region surrounding the tran-
scription start, resulting in enhanced transcription rate (Na-
kayama and Takami, 2001). A basic promoter should be
sufficient so that HDAC activity can take place. Support for this
concept was obtained from our work demonstrating that the
first 49 bp of the Abcd2 promoter enable PBA and butyrate to
activate a reporter gene and that the first 83 bp enable full in-
duction. In transient transfection experiments, we demonstrated
that the PBA-dependent induction and the basal level of expres-
sion of Abcd2 depends on the GC1 and CCAAT boxes. Both
motifs were shown to bind their cognate factors Sp1/Sp3 and
NF-Y, respectively, and we demonstrated that HDAC-1 is re-
cruited through the GC1 box in agreement with previous papers
(Doetzlhofer et al., 1999). Expression of Abcd2 probably results
from the balanced action of HAT and HDAC activities. The
CCAAT box, which binds NF-Y, likely allows HAT activity to
be recruited and to antagonize the effect of HDAC-1 (Jin and
Scotto, 1998). The recruitment of HAT activity may depend not
only on NF-Y but also on Sp1, as it has already been described
for the promoter of HDAC1 for instance (Schuettengruber et al.,
2003). It would explain why basal activity of the Abcd2 pro-
moter is reduced when the GC1 box is mutated, whereas it
might have been expected that this mutation results in enhanced
promoter activity because HDAC1 is not recruited anymore.
This would also be in agreement with the up-regulation of HAT
activity by physical interaction with Sp1 (Soutoglou et al.,
2001). Besides, it was shown that the effect of PBA on Abcd2
expression strictly depends on the presence of the GC1 box and
consequently on the recruitment of HDAC1. However, full in-
duction has been observed only when the CCAAT box is
present, suggesting a synergistic effect of the two motifs.
HDAC inhibition could increase recruitment of HAT to the
CCAAT box as it has already been hypothesized for the T RII
gene (Park et al., 2002). Further work would be necessary to de-
fine more precisely the complexes containing HAT and HDAC
activities and to show if other HDACs of the class I (Marks et
al., 2003) can be involved in Abcd2 expression.
We have shown that fibrates induce Abcd2 expression in
the liver of rodents in a PPAR -dependent way but not in the
brain (Albet et al., 1997; Berger et al., 1999; Fourcade et al.,
2001). It was believed that the absence of effects in brain was
due to their inability to cross the blood–brain barrier. Actually,
the present study revealed that fibrate, a powerful PP, has no
effect in glial cells and fibroblasts. This lack of effect suggests
that any drug, which requires PPAR , is likely to be ineffective
in inducing Abcd2 expression and in restoring VLCFA  -oxi-
dation in the brain of Abcd1  /  mice or X-ALD patients.
PBA might be a better candidate for a pharmacological therapy
of X-ALD because we showed that it can induce Abcd2 expres-
sion in glial cells and cause peroxisome proliferation. An in-
creased number of peroxisomes could contribute to improve
VLCFA metabolism in X-ALD patients. However, it is still un-
clear whether or not the correction of VLCFA levels observed
in the brain of Abcd1  /  mice after PBA treatment (Kemp et
al., 1998) results from enhanced Abcd2 expression. A high ef-
fective dose and a decreased response in long-term studies are
two stumbling blocks in using PBA for a therapy (McGuinness
et al., 2001). In an effort to identify nontoxic agents effective at
a low dose and with a long-term effect, we searched for the
mechanism of pharmacological induction of Abcd2 by PBA.
We show that PBA acts at the peroxisomal level probably by
inhibiting HDAC activity, like butyrate, suggesting that other
HDAC inhibitors should be tested. Two compounds structur-
ally related to PBA (styrylacetate and benzyloxyacetate) were
shown to be as efficient as PBA in increasing VLCFA peroxi-
somal  -oxidation in Abcd1  /  mice fibroblasts (McGuin-
ness et al., 2001). It would be of great interest to assess the
potential of these two analogues on Abcd2 expression in oligo-
dendrocytes, the myelin-forming cells.
There is a priori concern regarding the use of HDAC inhib-
itors because of their nonspecific effects on gene expression, but
in clinical trials several HDAC inhibitors appeared to be well tol-
erated (Marks et al., 2003). Investigation of pharmacological
agents acting through another molecular mechanism should also
be considered. A more comprehensive understanding of the ex-
pression of the Abcd2 gene is needed to identify other drugs for
the development of an effective pharmacological therapy.
Materials and methods
Animals and treatments
Male Wistar rats of  200 g (Charles River Laboratories) were kept at 22 C
with equal periods of darkness and light and had free access to water and
food. PBA (Sigma-Aldrich) was delivered to rats (n   6) in their chow (7.5
g/kg) and water (10 g/L) corresponding to dose  1 for 6–7 wk. A higher
dose of PBA (dose  1.5), corresponding to 11.3 g/kg of chow and 15 g/L
of water, was also given to rats (n   4) for 6–9 wk. The daily PBA uptake
was estimated to be  0.4–0.5 g per day per rat. The daily increase in
body weight was significantly lower in treated animals (2.9 g) than in con-
trols (5.3 g). Moreover, rats (n   3) received 720 mg PBA per kilogram of
body weight per day for 3 d via i.p. injections with an aqueous solution of
PBA (40 mg/ml) twice a day. They were killed 12 h after the last injection.
Rats (400 g) were anesthetized with pentobarbital (60 mg/kg,
i.p.). Drugs were administered at a delivery rate of 100  l/h through a
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ther 2 mg of sodium ciprofibrate (n   4) or 20 mg of PBA (n   4) dis-
solved in a total volume of 100  l of sterile water (pH adjusted at 7.3).
Control rats (n   4) received equiosmolar amounts of NaCl (100  l). The
rats were killed 48 h after injection.
Cell culture
Rat primary hepatocytes were prepared as described previously (Fourcade
et al., 2001). Mouse primary hepatocytes were obtained according to
Maslansky and Williams (1982), and a transfer on a cushion of Percoll
yielded 90% viability. Differentiated CG4 rat glial cells, pure primary asto-
cytes, and mixed primary culture of oligodendrocytes and astrocytes were
obtained and cultured as described previously (Fourcade et al., 2003).
Embryonic fibroblasts were prepared from 14-d-old fetuses of PPAR   / 
and  /  mice as described previously (Doetschman et al., 1985) and cul-
tured in DME supplemented with 10% FCS. COS-7 cells were grown in
DME supplemented with 10% FCS in the absence of antibiotics.
Northern blot analysis
Total RNA was extracted from rat tissues using a standard protocol. The
GenElute Mammalian Total RNA kit (Sigma-Aldrich) was used to prepare
RNA from cultured cells. Membranes containing 20  g per lane of RNA
were hybridized with  -[
32P]–labeled cDNA probe as described previ-
ously (Albet et al., 2001).
Semiquantitative RT-PCR
Total RNA was reverse-transcribed by random priming. To study Aox ex-
pression, PCR was performed as described previously (Fourcade et al.,
2001). Abcd2 cDNA was amplified using the forward (F) and reverse (R)
primers 5 -GTGTATGCCACTGCTAAAG-3  and 5 -TCAGCTCCAGAG-
GCCAGT-3 , respectively, for 27 cycles (30 cycles when RNA was ex-
tracted from primary hepatocytes) and 56 C as the annealing tempera-
ture. Amplification of 36b4 cDNA was performed using the primers 5 -
AAYGTGGGCTCCAAGCAGATG-3  (F) and 5 -GAGATGTTCAYCATGT-
TCAGCAG-3  (R), for 17 cycles and 60 C as the annealing temperature.
PCR products were analyzed on agarose gels and quantified by digital
imaging, and the relative abundance of mRNA was determined by com-
parison with 36b4 mRNA level.
Microscopy
Rats were anesthetized and the tissues were fixed through intracardial per-
fusion with fixative. Peroxisomes were visualized by staining for catalase
activity with DAB (Roels et al., 1995). Immunolocalization of AOX (anti-
body provided by A. Völkl, University of Heidelberg, Heidelberg, Ger-
many) or catalase for LM or EM was performed according to Espeel and
Van Limbergen (1995). LM images were photographed on film on an Aris-
toplan microscope (Leitz) using 63 , 1.4 NA, and 40 , 0.75 NA, oil
immersion lenses (Leitz) for bright field and phase contrast and on an in-
verted microscope (model DMIRB; Leica) using a Leica PL Apo 63 , 1.32–
0.6 NA oil immersion lens, and the Leica MPS-60 photoautomat for im-
munofluorescence. On randomly taken LM micrographs, the number of
peroxisomes per cellular area was determined by counting catalase-stained
peroxisomes and measuring cellular area excluding blood vessels with a
semi-automatic image analysis system (Mini-Mop; Kontron). EM images
were photographed on a transmission electron microscope (model JEM-
100B; JEOL). Morphometry of peroxisomes was performed on random EM
micrographs as described previously (Kerckaert et al., 1995). Gold parti-
cles per peroxisome were counted and organelle area was measured with
the Mini-Mop apparatus. A nonparametric ranking test (Mann-Whitney)
was used for statistical analysis of microscopy data. For publication, mi-
crographs were scanned and imported into Adobe Photoshop.
Plasmid constructs
The first 83 bp of the rat Abcd2 promoter (relative to the transcription start
located at  194 from the translation start site) were cloned directionally
into pGL3-Basic (Promega) to yield p277 as described previously (Four-
cade et al., 2001). The p243 construct was prepared as p277 except that
the inserted PCR fragment was amplified using forward primer 5 -ttagatcT-
GAGAAGCCTGGG-3  containing a BglII site (underlined). The plasmids
p277 5UTR and p243 5UTR were built as p277 and p243 using the re-
verse primer 5 -CTGaAGCTTGCTCAAACTCCACCGC-3  (the HindIII site
is underlined). The constructs were verified by sequencing with GL primer
2 (Promega). p277 1, p277 2, and p277 1,2 were obtained from the
p277 plasmid by site-directed mutagenesis with the Quickchange site di-
rected mutagenesis kit (Stratagene) according to the manufacturer’s proto-
col using pairs of complementary oligonucleotides corresponding to the
following sequences: GC1 mut, 5 -CCAATGAGAAGCCTGGGGTTTG-
GAGCCTGGCCAGC-3 ; GC2 MUT, 5 -GGAGTCCAGGGTCTCAAAGC-
CCACGCAGCCAATGAG-3  (the GC boxes are shown in bold and muta-
tions are underlined).
Transient transfection experiments
COS-7 cells were transfected using Exgen 500 liposome (Euromedex) with
100 ng of pCMV- Gal (CLONTECH Laboratories, Inc.), 650 ng of
pGLUC (a modified pGL2 vector) or empty pGL3-Basic or construct, and
250 ng of empty pSG5 (Stratagene) as previously described (Fourcade et
al., 2001). The transfected cells were incubated with or without PBA or
butyrate for 36 h and assayed for luciferase activity (Fourcade et al.,
2001). Luciferase activity was corrected for transfection efficiency using
 -galactosidase activity.
EMSA
The following pairs of oligonucleotides used as probes or competitors in
EMSA were designed from the rat ABCD2 promoter: GC1 (F, 5 -agcttC-
CTGGGGGGTGGAGCCTGG-3 ; R, 5 -gatcCCAGGCTCCACCCCCCA-
GGa-3 ), GC1 mut (F, 5 -agcttCCTGGGGTTTGGAGCCTGG-3 ; R, 5 -
gatcCCAGGCTCCAAACCCCAGGa-3 ), CCAAT (F, 5 -agcttCCACGCA-
GCCAATGAGAAGCCg-3 ; R, 5 -gatccGGCTTCTCATTGGCTGCGTGGa-
3 ), CCAAT mut (F, 5 -agcttCCACGCCCCGTATTTGAAGCCg-3 ; R, 5 -
gatccGGCTTCAAATACGGGGCGTGGa-3 ) (GC1 and CCAAT boxes are
shown in bold; mutations are underlined; lower case letters are modified
nucleotides from the original sequence to create compatible ends for clon-
ing and fill-in labeling). Labeling of probes and binding experiments in the
presence of 10  g of nuclear extracts from rat liver were performed as de-
scribed previously (Fourcade et al., 2001). Competition and supershift ex-
periments were performed by adding a 50-fold molar excess of unlabeled
oligonucleotides or antibodies (Santa Cruz Biotechnology, Inc.; anti-Sp1,
anti-Sp3, and anti–NF-YA) or a rabbit serum (control) 30 min before the
addition of the radiolabeled probes. The samples were analyzed by elec-
trophoresis at 4 C on 4% polyacrylamide gels in 0.5   TBE (45 mM Tris-
borate and 1 mM EDTA).
DAPA
Complementary oligonucleotides corresponding to the normal (5 -TGA-
GAAGCCTGGGGGGTGGAGCCTGGCCAG-3 ) or mutated (5 -TGAG-
AAGCCTGGGGTTTGGAGCCTGGCCAG-3 ) GC1 box were synthesized,
biotinylated at their 5  termini, and annealed. The DAPA was performed
in a total volume of 400  l by mixing 4  g of biotinylated DNA probe
with 50  g of nuclear extracts from rat liver in binding buffer (20 mM Hepes,
pH 7.9, 10% glycerol, 50 mM KCl, 0.2 mM EDTA, 1.5 mM MgCl2, 10
 M ZnCl2, 1 mM DTT, and 0.25% Triton X-100). After a 30-min preincu-
bation on ice, 50  l of streptavidin-agarose beads (Novagen) were
added and incubated for 2 h under agitation. Beads were collected by a
brief centrifugation and washed twice in binding buffer. Proteins were
eluted in 15  l of SDS-PAGE loading buffer by heating for 5 min at 95 C.
After centrifugation, the supernatant was loaded on SDS-PAGE and West-
ern blot analysis was performed using anti-HDAC1 antibody (Santa Cruz
Biotechnology, Inc.).
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